Literature DB >> 24821976

Controversies in breast cancer screening for women aged 40-49 years.

Akihiko Suzuki1, Takanori Ishida2, Noriaki Ohuchi3.   

Abstract

Mammography is the only method of breast cancer screening that has established evidence of a mortality reduction. However, mammography does not achieve sufficient accuracy in the high-density breasts of patients<50 years of age. In 2009, the US Preventive Services Task Force revised its recommendation for breast cancer screening in women aged 40-49 years from Grade B to C because the net benefit was relatively small for this age bracket. The net benefit of screening is the sum of benefits and harm and should always be monitored especially in population screening. A high recall rate, an inefficient number needed to invite for screening to prevent one breast cancer death, a high false-positive rate and unnecessary additional imaging for women aged 40-49 years are great concerns of mammography screening. Overdiagnosis is also a detriment of mammography screening; however, it may have a limited effect on women aged 40-49 years. Establishment of new evidence for breast cancer screening, such as ultrasonography screening, is needed in order to create a more effective screening system.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  breast cancer screening; harm; mammography; net benefit; ultrasonography

Mesh:

Year:  2014        PMID: 24821976     DOI: 10.1093/jjco/hyu054

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  Challenges With Identifying Indication for Examination in Breast Imaging as a Key Clinical Attribute in Practice, Research, and Policy.

Authors:  Julie E Weiss; Martha Goodrich; Kimberly A Harris; Rachael E Chicoine; Marie B Synnestvedt; Steve J Pyle; Jane S Chen; Sally D Herschorn; Elisabeth F Beaber; Jennifer S Haas; Anna N A Tosteson; Tracy Onega
Journal:  J Am Coll Radiol       Date:  2016-10-13       Impact factor: 5.532

Review 2.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

3.  Focused Decision Support: a Data Mining Tool to Query the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Dataset and Guide Screening Management for the Individual Patient.

Authors:  Arjun Sharma; Jason Hostetter; James Morrison; Kenneth Wang; Eliot Siegel
Journal:  J Digit Imaging       Date:  2016-04       Impact factor: 4.056

4.  Diagnostic and therapeutic path of breast cancer: effectiveness, appropriateness, and costs--results from the DOCMa study.

Authors:  Maria Rosaria Giovagnoli; Adriana Bonifacino; Cosimo Neglia; Marco Benvenuto; Francesco Vincenzo Sambati; Lorenzo Giolli; Alessandra Giovagnoli; Prisco Piscitelli
Journal:  Clin Interv Aging       Date:  2015-04-17       Impact factor: 4.458

5.  Overdiagnosis: epidemiologic concepts and estimation.

Authors:  Jong-Myon Bae
Journal:  Epidemiol Health       Date:  2015-02-10

6.  Limitations of mammography in the diagnosis of breast diseases compared with ultrasonography: a single-center retrospective analysis of 274 cases.

Authors:  Hong Zhao; Liwei Zou; Xiaoping Geng; Suisheng Zheng
Journal:  Eur J Med Res       Date:  2015-04-21       Impact factor: 2.175

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.